Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma

More than 50% of human cancers harbor TP53 mutations and increased expression of Mouse double minute 2 homolog (MDM2), which contribute to cancer progression and drug resistance. Renal cell carcinoma (RCC) has an unusually high incidence of wild-type p53, with a mutation rate of less than 4%. MDM2 i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Joon Hee, Lee, Seon-Hyeong, Lee, Jae-Seon, Oh, Su-Jin, Ha, Ji Sun, Choi, Hyun-Jung, Kim, Soo-Youl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349864/
https://www.ncbi.nlm.nih.gov/pubmed/32560270
http://dx.doi.org/10.3390/cells9061475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349864/
https://www.ncbi.nlm.nih.gov/pubmed/32560270
http://dx.doi.org/10.3390/cells9061475

Ejemplares similares